Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Caesars Entertainment Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $360.13 (market cap $9.43B), while Caesars Entertainment Inc trades at $29.62 (market cap $6.06B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap. Which is the better fit depends on your goals.
| BIO | CZR | |
|---|---|---|
Market Cap | $9.43B | $6.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $30.41 |
52-Week Low | $241.71 | $18.14 |
Enterprise Value | $9.18B | $29.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Caesars Entertainment (CZR) trades at $29.61, down 1.53% on the day, with a bearish technical signal and recent quarterly earnings misses. The company shows strong operating cash flow of $1.3 billion in 2025 but faces net losses and high debt levels. Recent news highlights a pending acquisition by Tilman Fertitta for $5.7 billion, which could reshape its future.
CZR presents a mixed outlook: low P/E and P/S ratios suggest value, but persistent losses and high leverage pose risks. The acquisition offers potential upside, yet execution and integration challenges remain. Investors should weigh the attractive valuation against fundamental weaknesses and market sentiment leaning cautious.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
